Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Phase I/II tral of NKT2152, an HIF-2α inhibitor, in pre-treated accRCC

Eric Jonasch • 15 Sep 2024
ESMO 2024
Genitourinary Cancer Kidney Cancer Belzutifan NKT2152

Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from a Phase I/II trial (NCT05119335) of NKT2152, an oral HIF-2α inhibitor, in patients with heavily pretreated advanced clear cell renal carcinoma (accRCC). There were dose escalation cohorts and additional cohorts that included patients resistant to belzutifan. NKT2152 showed encouraging efficacy in patients, and the safety profile was consistent with similar agents. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eric Jonasch

Evaluating the evolving role of belzutifan in renal cell carcinoma
1:13
Evaluating the evolving role of belzutifan in renal cell carcinoma
Eric Jonasch • 1 Jun 2025
STARLITE-1: 177Lu-Girentuximab, cabozantinib & nivolumab in ccRCC
0:54
STARLITE-1: 177Lu-Girentuximab, cabozantinib & nivolumab in ccRCC
Eric Jonasch • 1 Jun 2025
5-year follow-up results from LITESPARK-004
0:54
5-year follow-up results from LITESPARK-004
Eric Jonasch • 1 Jun 2025
Kidney cancer highlights from ASCO 2025
0:43
Kidney cancer highlights from ASCO 2025
Eric Jonasch • 1 Jun 2025

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals